Monte Rosa Therapeutics (GLUE) Competitors $4.59 -0.23 (-4.77%) Closing price 08/25/2025 04:00 PM EasternExtended Trading$4.70 +0.11 (+2.37%) As of 08/25/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE vs. NTLA, PGEN, ZYME, STOK, SION, SYRE, CRMD, VERV, CRON, and PRAXShould you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Intellia Therapeutics (NTLA), Precigen (PGEN), Zymeworks (ZYME), Stoke Therapeutics (STOK), Sionna Therapeutics (SION), Spyre Therapeutics (SYRE), CorMedix (CRMD), Verve Therapeutics (VERV), Cronos Group (CRON), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Monte Rosa Therapeutics vs. Its Competitors Intellia Therapeutics Precigen Zymeworks Stoke Therapeutics Sionna Therapeutics Spyre Therapeutics CorMedix Verve Therapeutics Cronos Group Praxis Precision Medicines Monte Rosa Therapeutics (NASDAQ:GLUE) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Is GLUE or NTLA more profitable? Monte Rosa Therapeutics has a net margin of 13.58% compared to Intellia Therapeutics' net margin of -908.48%. Monte Rosa Therapeutics' return on equity of 9.95% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics13.58% 9.95% 6.42% Intellia Therapeutics -908.48%-57.48%-45.04% Do institutionals & insiders hold more shares of GLUE or NTLA? 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 6.5% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer GLUE or NTLA? In the previous week, Intellia Therapeutics had 7 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 7 mentions for Intellia Therapeutics and 0 mentions for Monte Rosa Therapeutics. Intellia Therapeutics' average media sentiment score of 1.23 beat Monte Rosa Therapeutics' score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Monte Rosa Therapeutics Neutral Intellia Therapeutics Positive Which has more volatility & risk, GLUE or NTLA? Monte Rosa Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500. Do analysts recommend GLUE or NTLA? Monte Rosa Therapeutics presently has a consensus target price of $15.33, suggesting a potential upside of 234.06%. Intellia Therapeutics has a consensus target price of $29.05, suggesting a potential upside of 155.30%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Monte Rosa Therapeutics is more favorable than Intellia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.58 Which has better valuation and earnings, GLUE or NTLA? Monte Rosa Therapeutics has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$75.62M3.75-$72.70M$0.3612.75Intellia Therapeutics$57.88M21.11-$519.02M-$4.69-2.43 SummaryMonte Rosa Therapeutics beats Intellia Therapeutics on 10 of the 16 factors compared between the two stocks. Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition Export to ExcelMetricMonte Rosa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$297.68M$3.12B$5.82B$9.74BDividend YieldN/A2.24%4.40%4.08%P/E Ratio12.7520.7730.1625.84Price / Sales3.75345.85432.33103.25Price / CashN/A43.2325.7828.79Price / Book1.269.649.525.99Net Income-$72.70M-$54.08M$3.27B$265.29M7 Day Performance4.32%3.85%3.17%3.87%1 Month Performance-19.05%2.54%3.11%0.75%1 Year Performance-34.15%6.59%31.47%18.20% Monte Rosa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics2.5464 of 5 stars$4.59-4.8%$15.33+234.1%-27.5%$297.68M$75.62M12.7590NTLAIntellia Therapeutics4.6016 of 5 stars$10.13-0.8%$29.05+186.8%-51.8%$1.09B$57.88M-2.16600Positive NewsGap UpPGENPrecigen3.8467 of 5 stars$3.64+13.4%$8.25+126.6%+243.1%$1.08B$4.34M-8.67190High Trading VolumeZYMEZymeworks0.2096 of 5 stars$14.39+0.5%N/AN/A$1.08B$76.30M-14.83460STOKStoke Therapeutics4.444 of 5 stars$19.68+1.9%$25.57+29.9%+34.9%$1.08B$36.56M23.15100SIONSionna TherapeuticsN/A$23.74+4.3%$38.50+62.2%N/A$1.05BN/A0.0035News CoverageSYRESpyre Therapeutics2.4113 of 5 stars$16.78+2.6%$53.40+218.2%-35.1%$1.01B$890K-4.9473News CoverageAnalyst UpgradeCRMDCorMedix2.5846 of 5 stars$13.56+0.3%$16.71+23.3%+143.0%$1.01B$43.47M18.0830VERVVerve Therapeutics2.9302 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110CRONCronos Group0.3876 of 5 stars$2.56+5.8%N/A+10.9%$980.58M$117.61M51.20450PRAXPraxis Precision Medicines1.6918 of 5 stars$46.38+2.5%$85.88+85.2%-6.8%$976.30M$8.55M-3.77110 Related Companies and Tools Related Companies NTLA Alternatives PGEN Alternatives ZYME Alternatives STOK Alternatives SION Alternatives SYRE Alternatives CRMD Alternatives VERV Alternatives CRON Alternatives PRAX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLUE) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access